Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Research Report 2024
PEG-modified drugs (recombinant proteins/polypeptides) refer to the formation of PEG-modified complexes by covalently linking polyethylene glycol molecules to recombinant proteins or polypeptide drugs. This modification can endow the drug with many beneficial properties, improving its pharmacological and biological properties.
According to Mr Accuracy reports’s new survey, global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PEG-modified Drugs (Recombinant Proteins-Polypeptides) market research.
PEG-modified drugs have the following advantagesimproving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck Sharp & Dohme
Baxalta
Amgen
Roche
UCB S.A.
Enzon
Horizon Pharma
Biogen
SunBio
Qilu Pharmaceutical
Changchun Genescience Pharmaceutical
Xiamen Amoytop Biotech
Jiangsu Hengrui Pharmaceuticals
Hansoh Pharmaceuticak Group
CSPC Baike (Shandong) Biopharmaceutical
Xiamen Sano banger Biotechnology
Lunan Pharmaceutical Group
Xiamen Amoytop Biotech
JenKem Technology
Segment by Type
Jinyouli
Xin Rui Bai
Shenlida
Jin Saizeng
Pegbin
Fulaimei
Aido
Nonmyeloid Malignancy
Slow Growth in Children
Viral Hepatitis
Adult Type 2 Diabetes
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The PEG-modified Drugs (Recombinant Proteins-Polypeptides) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PEG-modified Drugs (Recombinant Proteins-Polypeptides) market research.
PEG-modified drugs have the following advantagesimproving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck Sharp & Dohme
Baxalta
Amgen
Roche
UCB S.A.
Enzon
Horizon Pharma
Biogen
SunBio
Qilu Pharmaceutical
Changchun Genescience Pharmaceutical
Xiamen Amoytop Biotech
Jiangsu Hengrui Pharmaceuticals
Hansoh Pharmaceuticak Group
CSPC Baike (Shandong) Biopharmaceutical
Xiamen Sano banger Biotechnology
Lunan Pharmaceutical Group
Xiamen Amoytop Biotech
JenKem Technology
Segment by Type
Jinyouli
Xin Rui Bai
Shenlida
Jin Saizeng
Pegbin
Fulaimei
Aido
Segment by Application
Nonmyeloid Malignancy
Slow Growth in Children
Viral Hepatitis
Adult Type 2 Diabetes
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The PEG-modified Drugs (Recombinant Proteins-Polypeptides) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices